For instance, the treatment with the VEGFR2 inhibitor Valatanib, which initially induces transient benefits as an antiangiogenic drug, mediates hypoxia and increased activation of pro-angiogenic cytokine/chemokine pathways involved in the promotion of tumor progression [165]. Here, KDR is linked to neoplasm.